The US Securities and Exchange Commission hit pause on Nasdaq PHLX’s plan to roll out Bitcoin index options, choosing to conduct a full review after the CME Group challenged the initial approval. This means the May 22 green light granted by SEC staff has been suspended indefinitely while the Commission decides the fate of the product.
Dispute Over Bitcoin’s Regulatory Classification
Nasdaq’s proposed options, trading under the ticker QBTC, aimed to offer cash-settled, European-style contracts linked directly to the CME CF Bitcoin Real Time Index, scaled down by a factor of 100. The final settlement would rely on the New York variant of the CME CF Bitcoin Reference Rate, also divided by 100. Position and exercise limits were capped at 24,000 contracts to manage risk.
Unlike options tied to shares of spot Bitcoin ETFs, which are classified as securities, QBTC would reference an index tracking Bitcoin’s price directly. This difference lies at the heart of the regulatory friction. Bitcoin itself is generally treated as a commodity under US derivatives law, making the product’s classification contentious.
CME’s Argument on Exclusive CFTC Jurisdiction
CME contends that Bitcoin options should fall exclusively under Commodity Futures Trading Commission oversight, as Bitcoin is a non-security commodity. They argue the Commodity Exchange Act grants the CFTC sole authority over these Bitcoin derivatives and claim the SEC staff overstepped its regulatory power by approving Nasdaq’s product.
After filing a legal challenge in June, CME’s appeal automatically suspended the SEC’s earlier approval, forcing the Commission to formally review the situation. The SEC hasn’t taken a stance yet and merely agreed to examine the dispute without endorsing or dismissing CME’s claims.
This standoff delays Nasdaq’s entry into the Bitcoin options market and highlights the murky boundaries between securities and commodities in crypto regulation. As the Commission weighs in, the outcome could set a key precedent for how Bitcoin-related financial products are governed in the US.
This material is for informational purposes only and does not constitute financial advice.
